Commentary|Videos|November 17, 2026

Selecting Patients With High-Risk Prostate Cancer for Perioperative ARPI Therapy

At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.

In an interview with CancerNetwork®, at the 44th Annual Chemotherapy Foundation Symposium (CFS), Martin Gleave, CM, MD, FRCSC, FACS, explained which patients with high-risk localized prostate cancer are most likely to benefit from perioperative treatment intensification with an androgen receptor pathway inhibitor (ARPI).

Gleave's comments follow results from the phase 3 PROTEUS trial (NCT03767244), in which apalutamide (Erleada) plus androgen deprivation therapy (ADT) given before and after radical prostatectomy improved metastasis-free survival vs placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer (hazard ratio, 0.80; 95% CI, 0.67-0.96). He noted that trials such as PROTEUS enrich for patients with higher-volume, high-grade disease, and that patients in the lower tier of high-risk disease already have high cure rates with current standards of care, leaving fewer events for additional therapy to prevent.

Gleave is a distinguished professor in the department of Urologic Sciences at the University of British Columbia in Vancouver, Canada.

Transcript:

CancerNetwork: Which patients with high-risk localized prostate cancer benefit most from perioperative androgen receptor pathway inhibitors?

Gleave: You have to recognize that localized prostate cancer is a wide spectrum of aggressiveness, histologically as well as genomically, from low to intermediate to high risk. Even within the high-risk cohort, there is a low tier, a high tier, and a very high-risk tier of nonmetastatic, high-risk localized prostate cancer. What studies such as [the phase 3 ENZARAD/ANZUP 1303 trial (NCT02446444)] are showing is that unless you enrich for higher-volume, high-grade cancers, the event rates from treating the lower-tier high-risk subgroup are too low. In other words, cure rates are reasonably high with current standards of care, such as ADT plus radiation in ENZARAD. Similarly, surgery monotherapy has a high cure rate in that group. The events you are trying to affect down the road are fewer, so it is harder to find a difference with additional therapy.

If a patient has a low-volume Gleason [grade group] 4 cancer with a prostate-specific antigen [PSA] level of 8 [ng/mL], even though he is high risk, he is low-tier high risk and does not benefit from the PROTEUS regimen. Indeed, PROTEUS and the [biomarker-directed Genomic Umbrella Neoadjuvant Study (GUNS; NCT04812366)] that I run enrich for high-volume, high-grade disease. They require multiple positive cores with Gleason pattern 4 or 5 and/or a PSA level above 20 [ng/mL], which is another marker of disease burden.

From a clinical judgment and patient selection perspective, the sweet spot is higher-volume, high-grade disease. However, if you are considering surgery, these patients still have to fall within the clinical judgment of resectability and appropriateness for surgery. You are not going to make somebody who is unresectable resectable with systemic therapy, and that is where surgical judgment comes in.

Reference

Taplin ME, Gleave M, Shore ND, et al. Perioperative apalutamide in high-risk localized prostate cancer. N Engl J Med. 2026;395(6):546-560. doi:10.1056/NEJMoa2603878


Related to this article